Atara Financial Statements From 2010 to 2024

ATRA Stock  USD 11.47  0.86  8.11%   
Atara Biotherapeutics financial statements provide useful quarterly and yearly information to potential Atara Biotherapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Atara Biotherapeutics financial statements helps investors assess Atara Biotherapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Atara Biotherapeutics' valuation are summarized below:
Gross Profit
63.6 M
Profit Margin
(2.90)
Market Capitalization
61.1 M
Enterprise Value Revenue
0.4363
Revenue
62.4 M
We have found one hundred twenty available fundamental signals for Atara Biotherapeutics, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to validate all of Atara Biotherapeutics prevailing market performance against the performance between 2010 and 2024 to make sure the company can sustain itself down the road. The current year's Market Cap is expected to grow to about 95.3 M, whereas Enterprise Value is forecasted to decline to about 86.6 M.

Atara Biotherapeutics Total Revenue

10.56 Million

Check Atara Biotherapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Atara Biotherapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 4.8 M, Selling General Administrative of 47.3 M or Other Operating Expenses of 196.3 M, as well as many indicators such as Price To Sales Ratio of 6.02, Dividend Yield of 0.0 or Days Sales Outstanding of 1.5 K. Atara financial statements analysis is a perfect complement when working with Atara Biotherapeutics Valuation or Volatility modules.
  
Check out the analysis of Atara Biotherapeutics Correlation against competitors.
For information on how to trade Atara Stock refer to our How to Trade Atara Stock guide.

Atara Biotherapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets302.7 M165.5 M240.9 M
Slightly volatile
Other Current Liabilities51 M48.5 M20.8 M
Slightly volatile
Total Current Liabilities149.3 M142.2 M46.1 M
Slightly volatile
Other Liabilities131.8 M125.5 M32.1 M
Slightly volatile
Property Plant And Equipment Net42.2 M58.8 M33.5 M
Slightly volatile
Accounts Payable6.1 M3.7 M4.9 M
Slightly volatile
Cash24.5 M25.8 M54.8 M
Slightly volatile
Non Current Assets Total44.3 M63.6 M35.2 M
Slightly volatile
Non Currrent Assets Other5.1 M4.8 M1.5 M
Slightly volatile
Other Assets0.951.0M
Slightly volatile
Cash And Short Term Investments49.1 M51.7 M179.7 M
Slightly volatile
Common Stock Total Equity12.1 K11.5 K5.1 K
Slightly volatile
Common Stock Shares OutstandingM4.2 M14.2 M
Very volatile
Liabilities And Stockholders Equity302.7 M165.5 M240.9 M
Slightly volatile
Non Current Liabilities Total128.6 M122.5 M44.7 M
Slightly volatile
Other Current Assets8.6 M6.3 M6.8 M
Slightly volatile
Total Liabilities278 M264.7 M90.8 M
Slightly volatile
Property Plant And Equipment Gross43.7 M74.7 M34.7 M
Slightly volatile
Total Current Assets96.8 M101.9 M194.9 M
Slightly volatile
Common Stock5.7 K11 K4.6 K
Slightly volatile
Property Plant Equipment6.9 M7.2 M21.4 M
Slightly volatile
Net Tangible Assets287 M145.6 M212.9 M
Slightly volatile
Short Term Investments24.6 M25.9 M146.8 M
Pretty Stable
Capital Surpluse1.1 B2.1 B820.9 M
Slightly volatile
Non Current Liabilities Other36.2 M39.3 M22.2 M
Slightly volatile
Short and Long Term Debt Total60.8 M57.9 M16.5 M
Slightly volatile
Short and Long Term Debt400 K450 K490 K
Slightly volatile
Short Term Debt12.8 M12.2 M3.3 M
Slightly volatile
Capital StockK11 K6.5 K
Slightly volatile
Long Term Debt Total195.2 K219.6 K239.1 K
Slightly volatile
Capital Lease Obligations40.9 M57.9 M24.5 M
Slightly volatile
Net Receivables21.1 M34.1 M7.3 M
Slightly volatile

Atara Biotherapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization4.8 M4.8 M4.3 M
Slightly volatile
Selling General Administrative47.3 M50.9 M37.9 M
Slightly volatile
Other Operating Expenses196.3 M284.6 M157.5 M
Slightly volatile
Research Development148.2 M224.8 M119 M
Slightly volatile
Total Operating Expenses195.5 M275.7 M156.9 M
Slightly volatile
Non Operating Income Net Other63.1 M60.1 M13 M
Slightly volatile
Interest Income3.2 M4.8 M2.4 M
Slightly volatile
Net Interest Income896.8 K944 K2.3 M
Pretty Stable
Reconciled Depreciation6.3 M4.9 M3.5 M
Slightly volatile
Selling And Marketing Expenses888.8 K999.9 K1.1 M
Slightly volatile

Atara Biotherapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation32.3 M45.4 M25.8 M
Slightly volatile
Capital Expenditures1.2 M1.2 M5.8 M
Pretty Stable
Total Cash From Financing Activities1.9 MM105.6 M
Pretty Stable
End Period Cash Flow24.7 M26 M56.9 M
Slightly volatile
Begin Period Cash Flow77 M93.1 M57.3 M
Slightly volatile
DepreciationM4.8 MM
Slightly volatile
Change To Netincome3.9 M4.1 M17.9 M
Slightly volatile
Issuance Of Capital Stock30.9 M32.6 M259.6 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio6.026.335259.237
Slightly volatile
Days Sales Outstanding1.5 K1.5 K228
Slightly volatile
Stock Based Compensation To Revenue5.565.29412.8986
Slightly volatile
Capex To Depreciation0.240.25333.9402
Very volatile
EV To Sales9.5710.071556.5317
Slightly volatile
Inventory Turnover0.870.91558.0797
Slightly volatile
Days Of Inventory On Hand41939957.136
Slightly volatile
Payables Turnover2.532.41210.7694
Slightly volatile
Sales General And Administrative To Revenue6.245.93823.9863
Pretty Stable
Average Inventory749.4 K713.7 K150.4 K
Slightly volatile
Research And Ddevelopement To Revenue27.5326.220114.9606
Slightly volatile
Capex To Revenue0.260.14270.4474
Slightly volatile
Cash Per Share11.612.2094214
Pretty Stable
Days Payables Outstanding1441515.1 K
Slightly volatile
Income Quality0.550.69890.6185
Slightly volatile
Current Ratio0.680.716211.9892
Slightly volatile
Receivables Turnover0.240.251316.6412
Slightly volatile
Graham Number1761851.5 K
Pretty Stable
Capex Per Share0.270.28873.2997
Pretty Stable
Revenue Per Share1.922.02365.6447
Very volatile
Interest Debt Per Share0.71.24750.5517
Slightly volatile
Operating Cycle1.9 K1.9 K285
Slightly volatile
Days Of Payables Outstanding1441515.1 K
Slightly volatile
Ebt Per Ebit1.331.00041.563
Slightly volatile
Quick Ratio0.620.64811.9793
Slightly volatile
Net Income Per E B T0.951.00018.8175
Slightly volatile
Cash Ratio0.170.18174.6907
Slightly volatile
Days Of Inventory Outstanding41939957.136
Slightly volatile
Days Of Sales Outstanding1.5 K1.5 K228
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.841.00631.0323
Pretty Stable
Fixed Asset Turnover0.140.14580.2796
Pretty Stable
Price Sales Ratio6.026.335259.237
Slightly volatile
Asset Turnover0.07040.05180.0542
Slightly volatile

Atara Biotherapeutics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap95.3 M62.5 M82.8 M
Slightly volatile

Atara Fundamental Market Drivers

Cash And Short Term Investments51.7 M

Atara Upcoming Events

14th of February 2024
Upcoming Quarterly Report
View
13th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
14th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Atara Biotherapeutics Financial Statements

Atara Biotherapeutics stakeholders use historical fundamental indicators, such as Atara Biotherapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Atara Biotherapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Atara Biotherapeutics' assets and liabilities are reflected in the revenues and expenses on Atara Biotherapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Atara Biotherapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue77.8 M81.7 M
Total Revenue8.6 M10.6 M
Cost Of Revenue8.9 M6.4 M
Stock Based Compensation To Revenue 5.29  5.56 
Sales General And Administrative To Revenue 5.94  6.24 
Research And Ddevelopement To Revenue 26.22  27.53 
Capex To Revenue 0.14  0.26 
Revenue Per Share 2.02  1.92 
Ebit Per Revenue(32.19)(33.80)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Atara Biotherapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Atara Biotherapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Atara Biotherapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Atara Biotherapeutics Stock:
Check out the analysis of Atara Biotherapeutics Correlation against competitors.
For information on how to trade Atara Stock refer to our How to Trade Atara Stock guide.
You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Atara Biotherapeutics. If investors know Atara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Atara Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(25.32)
Revenue Per Share
12.263
Quarterly Revenue Growth
28.927
Return On Assets
(0.57)
Return On Equity
(20.15)
The market value of Atara Biotherapeutics is measured differently than its book value, which is the value of Atara that is recorded on the company's balance sheet. Investors also form their own opinion of Atara Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Atara Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Atara Biotherapeutics' market value can be influenced by many factors that don't directly affect Atara Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Atara Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Atara Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Atara Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.